The risks of peptides split into two very different categories. Approved peptide medicines have characterized risks — named side effects, contraindications, and boxed warnings drawn from large trials. Unregulated research peptides carry mostly unknown medical risks plus concrete quality risks: wrong doses, impurities, and unverified ingredients. Treating these two categories as one thing is the most common mistake in this space.
Characterized risks: what an approved label looks like
When a peptide has been through full drug development, its risks are specific and written down. The Ozempic (semaglutide) prescribing information is a good model of the genre:
- A boxed warning for thyroid C-cell tumors seen in rodents, with the drug contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
- Acute pancreatitis, including rare fatal cases, observed across the GLP-1 class.
- Gallbladder disease — cholelithiasis in 1.5% of patients at the 0.5 mg dose in trials.
- Acute kidney injury linked to dehydration from nausea, vomiting, and diarrhea.
- Diabetic retinopathy complications, hypersensitivity reactions, and guidance to stop the drug at least two months before a planned pregnancy.
None of this makes semaglutide unusually dangerous — it makes it unusually well measured. Every item comes with frequency data from tens of thousands of trial participants, which is what allows benefit and risk to be weighed at all. The organ questions get fuller treatment on the liver and kidney pages.
Unknown risks: the research-peptide problem
Compounds like BPC-157, TB-500, or AOD-9604 have never been through that process. There is no label because there are no adequate human safety trials — which means the main risk is not a known side effect but the absence of the data that would reveal one. The FDA said this plainly when it reviewed peptides nominated for pharmacy compounding: for BPC-157 and several others it found "no, or only limited, safety-related information", flagged immunogenicity risks from peptide impurities and aggregation, and for CJC-1295 noted reported serious adverse events including increased heart rate. For MOTS-c, the agency could not identify any human exposure data for the compounded products at all.
Immunogenicity deserves emphasis because it is peptide-specific: injected peptides can provoke antibody and hypersensitivity responses, and impure or aggregated product makes that more likely — a risk that scales with exactly the quality problems described next.
Quality and sourcing risks
Even when the molecule itself is well understood, the vial may not be. The FDA's safety communication on unapproved GLP-1 drugs documents what went wrong when a proven peptide medicine was sold outside its approved form: adverse-event reports, some requiring hospitalization, tied to dosing errors with compounded semaglutide (patients drawing up the wrong volume from multi-dose vials, and clinicians miscalculating doses), plus products made from salt forms — semaglutide sodium and semaglutide acetate — which are different active ingredients that were never evaluated for safety or effectiveness.
If that is the record for a famous molecule sold through licensed compounders, the uncertainty for anonymous "research use only" vials — no verified identity, purity, sterility, or concentration — is strictly larger.
Regulatory and anti-doping risks
For athletes, the risk is not hypothetical. The WADA Prohibited List bans peptide hormones, growth factors, and related substances (class S2) at all times, in and out of competition — and its S0 category prohibits any substance without current regulatory approval for human use, naming BPC-157 explicitly as an example. A positive test does not depend on whether the product worked, and contaminated vials have caused violations from compounds users did not know they were taking. Outside sport, importing or distributing unapproved drugs raises its own legal questions that vary by jurisdiction.